Merck plans to launch US subcutaneous version of Keytruda on October 1
Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy ...
2 Beaten-Down Stocks to Buy and Hold for a Decade
Furthermore, Fiverr diligently cut costs and expenses and has now managed green on the bottom line for two consecutive years.
Fierce Pharma5d
Merck lays out subcutaneous Keytruda data in lung cancer amid patent brawl with Halozyme
Merck has filed a petition with the U.S. Patent and Trademark Office to challenge seven of Halozyme’s patents. Halozyme said ...
Devdiscourse3d
Global Health and Pharmaceutical Updates: From Cyberattacks to Drug Approvals
The health sector faces challenges as Novo Nordisk's sales projections dim, Johnson & Johnson's unit faces hefty fines, and ...
Top Stock Movers Now: Lululemon, Oxford Industries, WR Berkely, and More
Lululemon Athletica and Oxford Industries both warned that consumer spending is slowing. Merck anticipates putting an ...
10 Firms End Friday Strong; 3 Reach All-Time Highs
Despite the broader market downturn, 10 individual stocks showed a strong performance during the trading session, with three ...
Transgene Achieves Key Milestones in 2024, Including Clinical Proof of Principle for Individualized Cancer Vaccine ̶ Strong Outlook for 2025
Full-year results and business updateClinical proof of principle obtained in Phase I adjuvant head and neck cancer trial with individualized ...
devdiscourse5d
Merck to Launch Subcutaneous Keytruda: Revolutionizing Cancer Treatment
Merck plans to launch a subcutaneous version of its cancer immunotherapy drug Keytruda in the U.S. by October 1, pending FDA approval expected on September 23. This version will cut down ...